Thus, although none of the described GRPR- and PSMA-bispecific agents have been studied in a clinical context thus far, some of the developed radiotracers demonstrated high potential for bispecific and therefore highly sensitive PCa imaging during all stages of disease. This evidence concerns the gene FOLH1 and posterior cortical atrophy.